Ibti Pharma SRL
Ibti Pharma reported total assets of 660,797 € at the end of the 2025 financial year (annual accounts filed with the NBB on 21 Sep 2026).
The score of Ibti Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +57 % Total assets +131 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Ibti Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 21 Sep 2026
- Year ended 31 Dec 2024filed on 29 Jul 2025
- Year ended 31 Dec 2023filed on 26 Jul 2024
- Year ended 31 Dec 2022filed on 13 Sep 2023
Ibti Pharma's financial analysis
- Solvency47.8%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Ibti Pharma
Ibti Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0769.814.863
- VAT number
- BE0769814863
- Peppol
- Registered · 0208:0769814863 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 Jun 2021
- Registered office
- 7033 Mons
- Latest accounts
- 2025 · filed on 21 Sep 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Ibti Pharma (SRL) has been based in Mons since 2021, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 28,266 € and equity of 315,706 €; its revenue is not published. Its solvency stands at 47.8%, above the median of its sector (41.5%).
Companies similar to Ibti Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie de la Chasse Royale Retail sale of pharmaceutical products Frameries · balance sheet 657,047 €
- T.Lamote Retail sale of pharmaceutical products Merchtem · balance sheet 663,074 €
- Apotheek Debremaeker Retail sale of pharmaceutical products Halle · balance sheet 661,199 €
- Apoteek Geraerts Retail sale of pharmaceutical products Hasselt · balance sheet 660,254 €
- VAN DE Weyer Apotheek Retail sale of pharmaceutical products Landen · balance sheet 661,590 €
- Sophie Verreydt Retail sale of pharmaceutical products Lokeren · balance sheet 661,590 €
- Henrion-Fourez Retail sale of pharmaceutical products Brunehaut · balance sheet 661,950 €
- Corums Retail sale of pharmaceutical products Halle · balance sheet 662,462 €
Frequently asked questions about Ibti Pharma
What is the revenue of Ibti Pharma?
Ibti Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Ibti Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0769814863 for Ibti Pharma, if the company is VAT-registered. Its company number (CBE) is 0769.814.863.
Where is the registered office of Ibti Pharma?
According to the CBE register, the registered office of Ibti Pharma is in 7033 Mons.
What is the equity of Ibti Pharma?
At the close of the 2025 financial year, the equity of Ibti Pharma amounts to 315,706 €, a solvency of 47.8% of total assets.
Who manages Ibti Pharma?
The register lists 2 active mandates at Ibti Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Ibti Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →